Tobacco smoking as a chronic disease: Notes on prevention and treatment

Primary Care - Clinics in Office Practice

Volumn 29, Issue 3, 2002, Pages 629-648

  Van Dijk, Monique ^a   Peters, Jeroen W B ^a   Bouwmeester, Nancy J ^a   Tibboel, Dick ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CATAPRESS; CLONIDINE; MONOAMINE OXIDASE INHIBITOR; NICORETTE MINT; NICOTINE; NICOTINE GUM; NORTRIPTYLINE; UNCLASSIFIED DRUG;

BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; DOCTOR PATIENT RELATION; DOPAMINERGIC SYSTEM; ENVIRONMENTAL FACTOR; GENETIC POLYMORPHISM; HEALTH CARE COST; HEALTH EDUCATION; HEREDITY; HETEROZYGOSITY; HUMAN; HYPOTENSION; INSOMNIA; NEUROTRANSMISSION; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SELF EVALUATION; SKIN IRRITATION; SLEEP DISORDER; SMOKING; SMOKING CESSATION; SMOKING HABIT; SOCIAL ASPECT; TOBACCO DEPENDENCE; UNITED STATES; VERTIGO; XEROSTOMIA;

CHRONIC DISEASE; HUMANS; PRIMARY PREVENTION; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 0036718384     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(02)00016-7     Document Type: Review

References (149)

1. Mortality from smoking worldwide
2. Smoking-attributable mortality and years of potential life lost - United States, 1984
3. Who's smoking now? The epidemiology of tobacco use in the United States and abroad
4. Cigarette smoking among adults - United States, 1999
5. Medical-care expenditures attributable to cigarette smoking - United States, 1993
6. State estimates of total medical expenditures attributable to cigarette smoking, 1993
7. Molecular and cellular aspects of nicotine abuse
8. The legal and scientific basis for FDA's assertion of jurisdiction over cigarettes and smokeless tobacco
9. Mesolimbic dopamine activation - The key to nicotine reinforcement?
10. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
11. Cigarette smoking among adults - United States, 1993 and 1994
12. Cigarette smoking among adults - United States, 1995
13. A longitudinal analysis of predictors of quitting smoking among participants in a self-help intervention trial
14. Smoking cessation during previous year among adults - United States, 1990 and 1991
15. Smoking cessation treatment and the good doctor club
16. Improving compliance and increasing control of hypertension: Needs of special hypertensive populations
17. Compliance with pulmonary medication in general practice
18. Dropout and relapse during diabetes care
19. Compliance to treatment
20. Predictors of physician's smoking cessation advice
21. Validation of susceptibility as a predictor of which adolescents take up smoking in the United States
22. Parental influences predict adolescent smoking in the United States, 1989-1993
23. Identification of adolescents at risk for smoking initiation: Validation of a measure of susceptibility
24. The natural history of cigarette smoking: Predicting young-adult smoking outcomes from adolescent smoking patterns
25. Parent educational attainment and adolescent cigarette smoking
26. Which adolescent experimenters progress to established smoking in the United States
27. Youth tobacco surveillance - United States, 2000
28. Tobacco industry promotion of cigarettes and adolescent smoking
29. Changes in the cigarette brand preferences of adolescent smokers - United States, 1989-1993
30. New directions in the genetic mechanisms underlying nicotine addiction
31. Cancer and smoking
32. Lung cancer and cigarettes
33. Genetic influence on smoking - A study of male twins
34. Heritability of substance use in the NAS-NRC Twin Registry
35. Evidence for genetic influences on smoking in adult women twins
36. Twin concordance for a binary trait. II. Nested analysis of ever-smoking and ex-smoking traits and unnested analysis of a "committed-smoking" trait
37. Genetic contribution to risk of smoking initiation: Comparisons across birth cohorts and across cultures
38. Genetic models for the natural history of smoking: Evidence for a genetic influence on smoking persistence
39. A population-based twin study in women of smoking initiation and nicotine dependence
40. Genetic and environmental contributions to smoking
41. Heritability of conventional and ambulatory blood pressures. A study in twins
42. Are there interactions and relations between genetic and environmental factors predisposing to high blood pressure?
43. Genetics of asthma and hay fever in Australian twins
44. A population-based study of bronchial asthma in adult twin pairs
45. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland
46. Concordance rates of insulin dependent diabetes mellitus: A population based study of young Danish twins
47. Genetic influences on acute responses to nicotine and nicotine tolerance in the mouse
48. Genotype influences the development of tolerance to nicotine in the mouse
49. Genetic influences on nicotine responses
50. Classical genetic analysis of nicotine-induced seizures and nicotinic receptors
51. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes
52. Nicotine metabolism defect reduces smoking
53. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk
54. Debrisoquine metabolic ratio distribution differs between smokers and non smokers
55. CYP2D6 genotype and smoking behaviour in cigarette smokers
56. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele
57. The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking
58. D2 dopamine receptor gene and cigarette smoking: A reward gene?
59. Lack of association between the dopamine D2 receptor gene allele DRD2*A1 and cigarette smoking in a United Kingdom population
60. Incidence of initiation of cigarette smoking - United States, 1965-1996
61. Tobacco use among high school students - United States, 1997
62. How many adolescents start smoking each day in the United States?
63. The Master Settlement Agreement with the tobacco industry and cigarette advertising in magazines
64. Do anti-smoking media campaigns help smokers quit?
65. Effectiveness of the California 1990-1991 tobacco education media campaign
66. Evaluation of antismoking advertising campaigns
67. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents: Final rule
68. Cigarette taxes. The straw to break the camel's back
69. U.S. tobacco taxes: Behavioural effects and policy implications
70. The effect of cigarette taxes on cigarette consumption, 1955 through 1994
71. The effect of state cigarette tax increases on cigarette sales, 1955 to 1988
72. A meta-analysis of the California school-based risk reduction program
73. Mass media and school interventions for cigarette smoking prevention: Effects 2 years after completion
74. Relative effectiveness of comprehensive community programming for drug abuse prevention with high-risk and low-risk adolescents
75. Essential elements of school-based smoking prevention programs
76. Smoking status as a vital sign
77. Impact of chart reminders on smoking cessation practices of pulmonary physicians
78. Smoking status as the new vital sign: Effect on assessment and intervention in patients who smoke
79. Including smoking status as a new vital sign: It works!
80. Physician advice to quit smoking: Results from the 1990 California Tobacco Survey
81. How does physician advice influence patient behavior? Evidence for a priming effect
82. The physician-delivered smoking intervention project: Can short-term interventions produce long-term effects for a general outpatient population?
83. Physician advice for smoking cessation
84. A clinical practice guideline for treating tobacco use and dependence. A US Public Health Service report
85. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials
86. Nicotine replacement therapy for smoking cessation
87. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation
88. Nicotine replacement therapy for patients with coronary artery disease
89. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy
90. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments
91. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis
92. Smoking cessation through the use of nicotine chewing gum: A double-blind trial in Thailand
93. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study
94. Randomised controlled trial of nicotine chewing gum
95. The use of nicotine chewing gum as an aid to stopping smoking
96. Nicotine-containing chewing gum in smoking cessation: A double blind trial with half year follow-up
97. Nicotine gum in smoking cessation: A placebo-controlled, double-blind trial
98. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial
99. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program
100. A double blind study of 2 mg versus 4 mg nicotine-gum in an industrial setting
101. The nicotine inhaler in smoking cessation
102. Efficacy of a nicotine inhaler in smoking cessation: A double-blind, placebo-controlled trial
103. Smoking reduction with oral nicotine inhalers: Double blind, randomised clinical trial of efficacy and safety
104. A double-blind trial of a nicotine inhaler for smoking cessation
105. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial
106. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation
107. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study
108. Efficacy of a nicotine nasal spray in smoking cessation: A placebo-controlled, double-blind trial
109. Randomised controlled trial of nasal nicotine spray in smoking cessation
110. Nicotine nasal spray with nicotine patch for smoking cessation: Randomised trial with six year follow up
111. Bupropion for smoking cessation: Predictors of successful outcome
112. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism
113. A comparison of sustained-release bupropion and placebo for smoking cessation
114. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
115. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking
116. A randomized trial of nortriptyline for smoking cessation
117. Antidepressants for smoking cessation
118. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial
119. A placebo-controlled study of three clonidine doses for smoking cessation
120. Clonidine for smoking cessation
121. Randomized, controlled trial of transdermal clonidine for smoking cessation
122. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial
123. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation
124. Clonidine for smoking cessation
125. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy
126. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone
127. Anxiolytics for smoking cessation
128. Rapid smoking therapy safe and effective in COPD and CHD patients
129. Aversive cigarette smoking as a smoking cessation procedure
130. Hypnotherapy for smoking cessation
131. Acupuncture for smoking cessation
132. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial
133. National patterns in the treatment of smokers by physicians
134. Rates of US physicians counseling adolescents about smoking
135. Physicians counseling smokers. A population-based survey of patients' perceptions of health care provider-delivered smoking cessation interventions
136. Health beliefs of Pennsylvania physicians regarding smoking cessation counseling
137. Tobacco dependence curricula in US undergraduate medical education
138. Worldwide survey of education on tobacco in medical schools
139. Pediatric residency training on tobacco
140. Training pediatric residents to prevent tobacco use
141. Tobacco prevention education in a pediatric residency program
142. A residents' training program for the development of smoking intervention skills
143. Impact of a comprehensive health promotion curriculum on physician behavior and attitudes
144. Training family practice and internal medicine residents to counsel patients who smoke: Improvement and retention of counseling skills
145. Cigarette smoking: The clinician's role in cessation, prevention, and public health
146. Public health implications of voters' attitudes regarding statewide tobacco policy
147. Public policy for the control of tobacco-related disease